Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial

Open access
McGowan, Barbara M, Bruun, Jens M, Capehorn, Matt, Pedersen, Sue D, Pietiläinen, Kirsi H, Muniraju, Hanna Angelene Kudiyanur, Quiroga, Maria, Varbo, Anette, Lau, David C W · 2024 · The Lancet Diabetes & Endocrinology

Abstract

BACKGROUND There are currently limited data regarding the effect of semaglutide 2·4 mg in individuals with obesity and prediabetes in clinical trials. We aimed to assess the efficacy and safety of semaglutide 2·4 mg for weight management and glycaemic control in participants with obesity and prediabetes. METHODS STEP 10 was a randomised, double-blind, parallel-group, phase 3 trial done across 30 trial sites in Canada, Denmark, Finland, Spain, and the UK and included participants aged 18 years or older with a BMI of 30 kg/m2 or higher and prediabetes according to UK National Institute for Health and Care Excellence criteria (defined as having at least one of the following at screening: HbA1c of 6·0-6·4% [42-47 mmol/mol] or fasting plasma glucose [FPG] of 5·5-6·9 mmol/L). Participants were randomly assigned (2:1) to once-weekly subcutaneous semaglutide 2·4 mg or placebo with diet and physical activity counselling for 52 weeks, followed by a 28-week off-treatment period. Primary endpoints were percentage change in bodyweight and proportion of participants reverting to normoglycaemia (HbA1c <6·0% [<42 mmol/mol] and FPG <5·5 mmol/L) at week 52 (assessed in all randomly assigned participants by intention to treat). Selective safety data were collected for participants who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT05040971, and is complete. FINDINGS Between Sept 16 and Dec 29, 2021, 138 participants were randomly assigned to semag…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(24)00182-7

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 34 references

Research works printed but not linked: 1

  1. Rubino, 2022, Efficacy and safety of semaglutide 2.4 mg by race and ethnicity poster abstracts: poster 343, Obesity, 30, 55

Cited by

See all 176

Metadata

Authors
McGowan, B. M., Bruun, J. M., Capehorn, M., Pedersen, S. D., Pietiläinen, K. H., Muniraju, H. A. K., Quiroga, M., Varbo, A., & Lau, D. C. W.
Affiliations
  • Guy's and St Thomas' NHS Foundation Trust (GB)
  • Aarhus University Hospital (DK)
  • The Rotherham NHS Foundation Trust (GB)
  • University of Helsinki (FI)
  • Novo Nordisk (Denmark) (DK)
  • University of Calgary (CA)
Corresponding author
McGowan, Barbara M
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2024-09
Volume
12
Issue
9
Pages
631-642
ISSN
2213-8587 (ISSN-L)
OpenAlex
W4401067215
Cited by
176
References
34
Citations by year
2026: 75 · 2025: 92 · 2024: 9
FWCI
57.97
Type
journal article
Language
en
Open access
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Työväentutkimus Vuosikirja (submittedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
semaglutide, obesity, prediabetes, weight management, glycemic control, HbA1c, fasting blood glucose, GLP-1 receptor agonists, diabetes prevention, adverse events, drug safety, subcutaneous administration
MeSH terms
Semaglutide, Adult, Aged, Blood Glucose, Double-Blind Method, Glucagon-Like Peptides, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Prediabetic State, Weight Loss, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. https://app.cochat.ai/papers/10.1016/s2213-8587(24)00182-7
The paper
McGowan, B. M., Bruun, J. M., Capehorn, M., Pedersen, S. D., Pietiläinen, K. H., Muniraju, H. A. K., Quiroga, M., Varbo, A., & Lau, D. C. W. (2024). Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(24)00182-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.